NCT02652052已完成1 期
Hematopoietic Stem Cell Transplant Survivors Study (HTSS Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Frailty
研究概览
简要总结
The investigators hope to find the proof of principle concept from this pilot study so that the investigators can design a clinical trial based on the results of the explanatory hypothesis.
详细描述
Hematopoietic Stem Cell Transplant (HSCT) survivors are at an increased risk for premature aging. No one has evaluated the biologic markers of premature aging and senescence in HSCT survivors and their correlation with clinical outcomes, lifestyle, and nutrition. The investigators will evaluate age-related changes in HSCT survivors, with specified measures of premature aging, and employ therapeutic opportunities based on targeting senescent cells by conducting the first in-human pilot study of senolytic drugs (in HSCT survivors utilizing a combination of senolytics).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Allogeneic HSCT patients surviving ≥ 1 year post-HSCT
- •Diagnosis of both malignant and non-malignant conditions as HSCT indications
- •HSCT survivors receiving any type of conditioning chemo/radiotherapy for HSCT
- •Ability to provide written and verbal informed consent
- •Age ≥ 18 years
- •Platelets > 50,000 per microliter
- •Hemoglobin (HB) > 9/dL
- •Absolute neutrophil count (ANC) > 1000 per microliter
排除标准
- •HSCT survivor with human immunodeficiency virus (HIV) infection
- •HSCT survivor with active hepatitis B or C HSCT survivor on any TKI for either Philadelphia chromosome positive cancers or for graft versus host disease (GVHD) treatments or for any other indication (e.g., imatinib for gastrointestinal stromal tumor [GIST], sorafenib for FLT3+ acute myeloid leukemia [AML] etc)
- •HSCT survivor with any post-transplant maintenance chemotherapy
- •Post-(allogeneic) transplant relapse of cancer
- •Active progressive CHRONIC chronic or overlap GVHD (per the National Institute of Health [NIH] chronic GVHD criteria)
- •Presence of uncontrolled psychiatric disorder
- •Patient unable to give informed consent
- •Extremely poor overall prognosis (<6 months as deemed by the primary transplant physician)
- •HSCT survivors with confirmed drug addiction
- •HSCT survivors with active coronary artery disease (CAD) [including angina] or active congestive heart failure (CHF)
- •International HSCT survivors in whom loss to follow-up would be a concern as deemed by primary transplant physician
- •Known hypersensitivity or allergy to dasatinib, or quercetin
- •Presence of uncontrolled lupus
- •Presence of uncontrolled pleural/pericardial effusions or ascites
- •Presence of active new cancer (solid or hematologic) except non-melanoma skin cancers
- •Presence of progeroid syndromes in family
- •Invasive fungal or viral infection not responding to appropriate antifungal or antiviral therapies.
- •Creatinine clearance < 60 mL/min/1.73 m2 based on the Cockcroft-Gault
- •Inability to tolerate oral medications
- •Presence or history of significant liver disease with total bilirubin and/or alkaline phosphatase (ALP) > 2 x upper limit normal (unless deemed to be due to Gilbert's syndrome) or as per clinical judgement
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN) or as per clinical judgement
- •Active progressive ACUTE graft-versus-host disease
- •Active progressive OVERLAP graft-versus-host disease
- •Patients taking medications that are sensitive substrates or substrates with a narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6 or strong inhibitors or inducers of CYP3A4(e.g. cyclosporine, tacrolimus or sirolimus). If antifungals are absolutely necessary from infectious disease perspective, then they will be allowed only if the levels are therapeutic. Levels will be checked at baseline and also at day +4 post intervention
- •Patients taking H2-antagonists or proton pump inhibitors
- •Patients on therapeutic doses of anticoagulants (e.g. warfarin, heparin, low molecular weight heparin, factor Xa inhibitors etc)
- •On antiplatelet agents (e.g. full dose aspirin, clopidogrel etc.). Baby aspirin if absolutely necessary from cardiac perspective will be allowed.
- •On any quinolone antibiotic therapy for treatment or for prevention of infections.
- •Corrected QT (QTc) > 450 msec. Common drugs that are well known in prolonging QTc include azithromycin, citalopram, escitalopram, fluconazole, and pentamidine. Baselines electrocardiogram (EKG) will be obtained in each patient and if QTc > 450 msec, then they will be excluded from the trial
研究组 & 干预措施
Group 1: Observational
Other
Standard of Care - Observation Only
干预措施: Standard of Care - Observation Only (Other)
结局指标
主要结局
Frailty
时间窗: Up to 180 days
Evaluate the association of frailty with measures of senescence in HSCT survivors - level of frailty as assessed by FRIED
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A pilot study for hematopoietic stem cell transplantation with post-transplantation cyclophosphamide and anti-thymoglobulin from HLA-mismatched related donor for non-malignant diseases (Halo-NM)on-malignant diseases (bone marrow failure, immunodeficiency, inborn errors of metabolism)JPRN-UMIN000026159ational Center for Child Health and Development9
已完成
2 期
Allogeneic Transplantation For Severe OsteopetrosisSevere OsteopetrosisNCT00775931Masonic Cancer Center, University of Minnesota7
终止
不适用
Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) for Patients With Severe Sickle Cell DiseaseSickle Cell DiseaseNCT04207320University of Chicago3
终止
1 期
SCID Bu/Flu/ATG Study With T Cell DepletionSevere Combined ImmunodeficiencyNCT02127892Neena Kapoor, M.D.9
已完成
3 期
Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT)Bone Marrow TransplantationCytomegalovirusNCT00330018Hadassah Medical Organization40